In individuals with lung adenocarcinoma, epidermal growth factor receptor (EGFR) gene mutations are common, and EGFR-tyrosine kinase inhibitors (EGFR-TKIs), a class of targeted molecular therapies, are widely used in clinical practice. Here, EGFR is linked to lung adenocarcinoma.